Alkermes Shares Slide as J&J Moves to End Some Royalty Payments
November 09 2021 - 11:16AM
Dow Jones News
By Colin Kellaher
Shares of Alkermes PLC fell sharply Tuesday after the
biopharmaceutical company said a unit of Johnson & Johnson was
partially terminating license agreements related to its NanoCrystal
technology.
Alkermes said the terminations by J&J's Janssen
Pharmaceutica NV affect know-how royalties related to sales of
products such as the antipsychotics Invega Sustenna and Trinza in
the U.S.
Alkermes said it disputes Janssen's assertion that it doesn't
use the licensed NanoCrystal technology in the products, and that
it would explore all options to enforce its contractual rights.
Dublin-based Alkermes also noted that it had been planning for a
wind down of the Janssen royalty payments in the coming years.
Analysts at Mizuho said it was unclear what has changed that led
J&J to terminate the agreements and no longer pay royalties
after paying them for many years.
Mizuho keeps its "buy" rating on Alkermes shares, saying the
J&J move doesn't change their long-term view of the company,
but the analysts trim their price target to $33 from $36 as they
conservatively remove the royalties from their model.
Alkermes shares were recently trading at $25.19, down 14.1%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 09, 2021 11:01 ET (16:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Oct 2023 to Oct 2024